Spyre Therapeutics (SYRE) Shares Outstanding (2015 - 2026)

Spyre Therapeutics has reported Shares Outstanding for 12 years, with the latest figure at $78.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 30.8% year-over-year to $78.8 million; the trailing twelve-month figure through Mar 2026 stood at $78.8 million (up 30.8% YoY), and the FY2025 full-year result was $78.2 million, up 29.76% from the prior year.
• Shares Outstanding for Q1 2026 stood at $78.8 million, up from $78.2 million in the prior quarter.
• The five-year high for Shares Outstanding was $78.8 million in Q1 2026, with the low at $2.0 million in Q1 2022.
• Historically, Shares Outstanding has averaged $34.9 million across 5 years, with a median of $36.6 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding plunged 95.97% — and 2024, when it surged 1467.38%.
• Spyre Therapeutics' Shares Outstanding stood at $2.6 million in 2022, then surged by 1279.38% to $36.1 million in 2023, then surged by 67.12% to $60.3 million in 2024, then gained by 29.76% to $78.2 million in 2025, then increased by 0.83% to $78.8 million in 2026.
• The last three Shares Outstanding figures came in at $78.8 million (Q1 2026), $78.2 million (Q4 2025), and $60.5 million (Q3 2025), per Business Quant data.